Zacks Research Has Negative Forecast for MMSI Q3 Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Investment analysts at Zacks Research cut their Q3 2027 EPS estimates for Merit Medical Systems in a report issued on Friday, July 17th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings per share of $0.97 for the quarter, down from their prior estimate of $0.98. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.62 per share. Zacks Research also issued estimates for Merit Medical Systems’ FY2027 earnings at $3.82 EPS and Q1 2028 earnings at $0.94 EPS.

Merit Medical Systems (NASDAQ:MMSI) last posted its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.10. The firm had revenue of $381.88 million during the quarter, compared to the consensus estimate of $377.59 million. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The company’s revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.86 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS.

A number of other brokerages have also weighed in on MMSI. JPMorgan Chase & Co. decreased their target price on Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Piper Sandler restated an “overweight” rating on shares of Merit Medical Systems in a research note on Friday, July 10th. Robert W. Baird set a $83.00 price objective on Merit Medical Systems in a report on Friday, May 1st. Barrington Research lowered their price objective on shares of Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating for the company in a research note on Monday, April 20th. Finally, Wells Fargo & Company dropped their target price on shares of Merit Medical Systems from $78.00 to $74.00 and set an “equal weight” rating on the stock in a report on Friday, May 1st. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Merit Medical Systems has an average rating of “Moderate Buy” and a consensus price target of $92.80.

Merit Medical Systems Stock Up 1.6%

Shares of NASDAQ:MMSI opened at $75.17 on Tuesday. The business’s 50 day moving average is $67.26 and its 200 day moving average is $72.42. The stock has a market cap of $4.48 billion, a P/E ratio of 32.54, a price-to-earnings-growth ratio of 2.30 and a beta of 0.52. Merit Medical Systems has a 52-week low of $59.74 and a 52-week high of $94.75. The company has a quick ratio of 3.46, a current ratio of 5.08 and a debt-to-equity ratio of 0.45.

Insiders Place Their Bets

In other Merit Medical Systems news, insider Brian G. Lloyd acquired 2,000 shares of the firm’s stock in a transaction dated Thursday, May 7th. The stock was purchased at an average price of $62.62 per share, for a total transaction of $125,240.00. Following the acquisition, the insider owned 2,000 shares in the company, valued at approximately $125,240. This trade represents a ? increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lynne N. Ward sold 5,000 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $62.61, for a total value of $313,050.00. Following the completion of the sale, the director directly owned 7,809 shares of the company’s stock, valued at $488,921.49. The trade was a 39.04% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Merit Medical Systems

Institutional investors have recently added to or reduced their stakes in the business. State Street Corp increased its holdings in shares of Merit Medical Systems by 1.5% during the fourth quarter. State Street Corp now owns 2,231,048 shares of the medical instruments supplier’s stock valued at $196,645,000 after acquiring an additional 32,459 shares in the last quarter. Conestoga Capital Advisors LLC lifted its stake in shares of Merit Medical Systems by 3.9% during the first quarter. Conestoga Capital Advisors LLC now owns 2,167,513 shares of the medical instruments supplier’s stock worth $149,407,000 after buying an additional 81,030 shares during the period. Fuller & Thaler Asset Management Inc. lifted its position in Merit Medical Systems by 12.7% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,077,796 shares of the medical instruments supplier’s stock worth $183,137,000 after acquiring an additional 234,682 shares during the period. Wellington Management Group LLP boosted its position in Merit Medical Systems by 7.0% in the fourth quarter. Wellington Management Group LLP now owns 1,327,013 shares of the medical instruments supplier’s stock valued at $116,963,000 after buying an additional 86,504 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Merit Medical Systems by 1.0% in the first quarter. Dimensional Fund Advisors LP now owns 1,237,298 shares of the medical instruments supplier’s stock worth $85,287,000 after acquiring an additional 12,285 shares during the period. Institutional investors and hedge funds own 99.66% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.